stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) Shares outstanding
ICON PLC's shares outstanding at the end of fiscal 2025 was $79.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $77.4M. Over the past ten years it has ranged from $53.3M (fiscal 2020) to $83.0M (fiscal 2024); the current reading is higher than 73% of that period. ICON PLC ranks 24th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $79.0M | (4.90%) |
| FY2024 | $83.0M | 0.38% |
| FY2023 | $82.7M | 0.30% |
| FY2022 | $82.5M | 21.16% |
| FY2021 | $68.1M | 27.75% |
| FY2020 | $53.3M | (1.93%) |
| FY2019 | $54.3M | (0.84%) |
| FY2018 | $54.8M | (0.11%) |
| FY2017 | $54.8M | (2.76%) |
| FY2016 | $56.4M | (6.44%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $77.4M | 0.04% |
| Jun 2026 | $77.4M | 0.14% |
| Mar 2026 | $77.3M | (2.16%) |
| Dec 2025 | $79.0M | 2.06% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| QGEN QIAGEN N.V. compare | $207.8M |
| ILMN Illumina, Inc. compare | $154.0M |
| GH Guardant Health, Inc. compare | $134.4M |
| DGX Quest Diagnostics Incorporated compare | $112.0M |
| RVTY Revvity Inc. compare | $111.8M |
| LH Labcorp Holdings Inc. compare | $81.6M |
| ICLR ICON PLC | $77.4M |
| CRL Charles River Laboratories International, Inc. compare | $48.6M |
| MEDP Medpace Holdings, Inc. compare | $28.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement